arrow
M

Munyaradzi Musvosvi

University of Cape Town
H指数:20
被引数:1,605

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Risk Factors for Immunological Sensitization to Mycobacterium tuberculosis and Progression to Incident TB Disease Among HIV-uninfected Adults in a High Burden Setting

HIV阴性成人对结核分枝杆菌的免疫致敏及进展为新发结核病的危险因素研究

2026-02-180
OAAI
Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis

儿童中无症状结核病与家庭内结核分枝杆菌暴露

2025-11-010
OAAI
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b–2a, double-blind, dose-escalation, randomised controlled trial

活减毒分枝杆菌结核疫苗,MTBVAC,在有无Mycobacterium tuberculosis致敏的成人中的研究:一项单中心、1b~2a期、双盲、剂量递增、随机对照试验

2025-04-150
OAAI
Safety, reactogenicity and immunogenicity of MTBVAC in newborns in a TB endemic area: a phase 2a randomized, double-blind, dose-defining trial
2023-12-170
OA
REL and BHLHE40 Variants Are Associated with IL-12 and IL-10 Responses and Tuberculosis Risk

REL和BHLHE40变异与IL-12和IL-10反应及结核病风险相关

2022-03-158
OA
Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung Compartments of Patients With Tuberculosis and Other Lung Diseases

来自结核病和其他肺部疾病患者血液和肺区室的人骨髓细胞的靶向基因表达谱

2022-03-086
OAAI
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial
2021-03-0186
OAAI
Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacterium tuberculosis Infection
2020-10-1617
OAAI
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines
2020-10-0914
OAAI
Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial
2018-04-01121
PREAI